Recent Advances in the Treatment of Neurodegenerative Diseases Based on GSH Delivery Systems
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Neurodegenerative diseases, such as Parkinson's disease (PD) and Alzheimer's disease(AD), are a group of pathologies characterized by a progressive and specific loss of certain brain cell populations. Oxidative stress, mitochondrial dysfunction, and apoptosis play interrelated roles in these disorders. It is well documented that free radical oxidative damage, particularly on neuronal lipids, proteins, DNA, and RNA, is extensive in PD and AD brains. Moreover, alterations of glutathione (GSH) metabolism in brain have been implicated in oxidative stress and neurodegenerative diseases. As a consequence, the reduced GSH levels observed in these pathologies have stimulated a number of researchers to find new potential approaches for maintaining or restoring GSH levels. Unfortunately, GSH delivery to the central nervous system (CNS) is limited due to a poor stability and low bioavailability. Medicinal-chemistry- and technology-based approaches are commonly used to improve physicochemical, biopharmaceutical, and drug delivery properties of therapeutic agents. This paper will focus primarily on these approaches used in order to replenish intracellular GSH levels, which are reduced in neurodegenerative diseases. Here, we discuss the beneficial properties of these approaches and their potential implications for the future treatment of patients suffering from neurodegenerative diseases, and more specifically from PD and AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455 · cited 1×
“GSH loss in PD is also accompanied by a reduction in mitochondrial complex I activity, which is regionally selective for the SNpc in PD and does not occur in related basal ganglia degenerative disorders [25].”
Oxidative Stress, Glutamate, and Neurodegenerative Disorders
Coyle, J. T., & Puttfarcken, P. (1993) · Science · doi:10.1126/science.7901908 · Cited by 3,762
Metabolism and functions of glutathione in brain
Dringen, R. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00060-x · Cited by 1,702
The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927
Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective
Ratnam, D. V., Ankola, D. D., Bhardwaj, V., Sahana, D. K., & Kumar, M. N. V. R. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.015 · Cited by 885 · cited 1×
“The effectiveness of exogenous antioxidants to protect tissues from oxidative stress in vivo depends on the antioxidant used, its physicochemical and biopharmaceutical properties, and its bioavailability at the site of action [88, 89].”
Review: Alzheimer's Amyloid β-Peptide-Associated Free Radical Oxidative Stress and Neurotoxicity
Varadarajan, S., Yatin, S., Aksenova, M., & Butterfield, D. A. (2000) · Journal of Structural Biology · doi:10.1006/jsbi.2000.4274 · Cited by 735
McManus, M. J., Murphy, M. P., & Franklin, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0552-11.2011 · Cited by 432 · cited 1×
“An ubiquinone derivative, mitoquinone mesylate or MitoQ, has been used to prevent oxidative damage in AD [51].”
Neuroprotective strategies involving ROS in Alzheimer disease
Dumont, M., & Beal, M. F. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.11.026 · Cited by 402
Spencer, J. P. E., Jenner, P., Daniel, S. E., Lees, A. J., Marsden, D. C., & Halliwell, B. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71052112.x · Cited by 373
Oxidative imbalance in patients with mild cognitive impairment and Alzheimer’s disease
GUIDI, I., GALIMBERTI, D., LONATI, S., NOVEMBRINO, C., BAMONTI, F., TIRITICCO, M., FENOGLIO, C., VENTURELLI, E., BARON, P., & BRESOLIN, N. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.01.001 · Cited by 203 · cited 1×
“Furthermore, an emerging evidence indicates that the total antioxidant capacity (including GSH, ascorbic acid, uric acid, and bilirubin) has shown to be reduced by 24% in plasma samples from AD patients [49].”
Cited by
Oxidative stress, mitochondrial damage and neurodegenerative diseases.
Guo, C., Sun, L., Chen, X., & Zhang, D. (2013) · PubMed · doi:10.3969/j.issn.1673-5374.2013.21.009 · Cited by 1,298
The role of glutathione reductase and related enzymes on cellular redox homoeostasis network
Couto, N., Wood, J., & Barber, J. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.02.028 · Cited by 1,006
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Glutathione metabolism and Parkinson's disease
Smeyne, M., & Smeyne, R. J. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.05.001 · Cited by 435
Achieving Life through Death: Redox Biology of Lipid Peroxidation in Ferroptosis
Bayır, H., Anthonymuthu, T. S., Tyurina, Y. Y., Patel, S. J., Amoscato, A. A., Lamade, A. M., Yang, Q., Vladimirov, G. K., Philpott, C. C., & Kagan, V. E. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.03.014 · Cited by 317
Chelation: Harnessing and Enhancing Heavy Metal Detoxification—A Review
Sears, M. E. (2013) · The Scientific World Journal · doi:10.1155/2013/219840 · Cited by 307
The emerging role of glutathione in Alzheimer’s disease
Saharan, S., & Mandal, P. K. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132483 · Cited by 168
Liao, J.-F., Cheng, Y.-F., You, S.-T., Kuo, W.-C., Huang, C.-W., Chiou, J.-J., Hsu, C.-C., Hsieh-Li, H.-M., Wang, S., & Tsai, Y.-C. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.07.036 · Cited by 159
Oxidant Stress and Signal Transduction in the Nervous System with the PI 3-K, Akt, and mTOR Cascade
Maiese, K., Chong, Z. Z., Wang, S., & Shang, Y. C. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131113830 · Cited by 109
“Oxidative stress can lead to cognitive loss [14,18–20], Alzheimer’s disease (AD) [1,13,20–24], Huntington’s disease (HD) [25–31], Parkinson’s disease [1,9,26,32–39], epilepsy [25,26,28,40–43], and acute injury such as during stroke and trauma [44–54].”
BackgroundHafiz, Z. Z., Amin, M. ‘. M., Johari James, R. M., Teh, L. K., Salleh, M. Z., & Adenan, M. I. (2020) · Molecules · doi:10.3390/molecules25040892 · Cited by 64
“According to an autopsy study, a magnitude of GSH depletion was found in the AD cingulated cortex and AD substantia innominate, and these unfavorable events were correlated with a decline in cognitive functions [67,68].”
BackgroundNatarajan, S., Govindaraju, A., Rajmohamed, M., Palanisamy, P., & Abdulkader, A. (2017) · Pharmacognosy Magazine · doi:10.4103/pm.pm_57_17 · Cited by 20
The Neuroprotective Potential of Betalains: A Focused Review
Ştefănescu, C., Voştinaru, O., Mogoşan, C., Crişan, G., & Balica, G. (2025) · Plants · doi:10.3390/plants14070994 · Cited by 10
“Their and anti-in fl ammatory properties could also be important for other, less-explored protective e ff ects in neurodegenerative diseases in which oxidative damage, in fl ammatory processes, and the accumulation of misfolded proteins represent key pathogenetic mechanisms [10,11].”
Metadata
- Authors
- Cacciatore, I., Baldassarre, L., Fornasari, E., Mollica, A., & Pinnen, F.
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-12
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- OpenAlex
- W2119610385
- Cited by
- 105
- References
- 14
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.